CTRI/2024/01/061642招募中3 期
A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) - CAPItello-292
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Adult females (pre-/peri-/ and post-menopausal), and adult males.
- •2.Metastatic or locally advanced disease with radiologic or clinical evidence of recurrence or progression or intolerance to last/current treatment
- •3.Histologically confirmed HR+/ HER2- breast cancer determined from the most recent tumour sample (primary or metastatic) per the American Society of Clinical Oncology and College of American Pathologists guideline. To fulfil the requirement of HR+ disease, a breast cancer must express ER with or without co-expression of progesterone receptor.
- •4.Adequate organ and bone marrow functions.
- •5.ECOG performance status 0 to 1
- •6.Consent to provide a mandatory FFPE tumour sample.
- •7.Eligible for fulvestrant therapy and at least one of the following: palbociclib or ribociclib, as per local investigator assessment.
- •8.Previous treatment with an ET (tamoxifen, AI, or oral SERD) as a single agent or in combination, with radiological evidence of breast cancer recurrence or progression while on, or within 12 months of, completing a (neo)adjuvant ET regimen
排除标准
- •Exclusion Criteria:
- •1.History of another primary malignancy except for malignancy treated with curative intent with no known active disease = 2 years before the first dose of study intervention and of low potential risk for recurrence.
- •2.Radiotherapy within 2 weeks prior to study treatment initiation.
- •3.Major surgery or significant traumatic injury within 4 weeks of the first dose of study treatment.
- •4.Persistent toxicities (CTCAE Grade >1) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss or peripheral sensory neuropathy) after consultation with the AstraZeneca study physician.
- •5.Spinal cord compression, brain metastases or leptomeningeal metastases unless these lesions are definitively treated (eg. radiotherapy, surgery) and clinically stable off steroids for management of symptoms for at least 4 weeks prior to study treatment initiation.
- •6.Any of the following cardiac criteria at screening:
- •(a). Mean resting corrected QT interval (QTcF): (i) Participants to be treated with palbociclib: QTcF = 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (ii) Participants to be treated with ribociclib: QTcF = 450 ms obtained from the average of 3 consecutive (triplicate) ECGs (iii) Participants to be treated with abemaciclib (Phase Ib only): QTcF = 470 ms obtained from the average of 3 consecutive (triplicate) ECGs (b). Any clinically important abnormalities in cardiac rhythm, conduction or morphology of resting ECG (eg, complete left bundle branch block, third-degree heart block) (c). Any factors that increase the risk of QTc prolongation or risk of arrhythmic events (d). Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure New York Heart Association (NYHA) grade = 2 (e). Uncontrolled hypotension (f) uncontrolled hypertension (g). Cardiac ejection fraction outside institutional range of normal or < 50% (whichever is higher)
- •7.uncontrolled or high grade or symptomatic arrhythmia and atrial fibrillation
- •8.Any of these clinically significant abnormalities of glucose metabolism at screening:
- •a.diabetes mellitus type I or type II requiring insulin treatment
- •b.HbA1c = 8.0% (63.9 mmol/mol)
- •9.Previous allogeneic bone marrow transplant or solid organ transplant.
- •10.Any prior treatment with, AKT, PI3K or mTOR inhibitors.
- •11.Prior treatment with CDK4/6 inhibitors in the metastatic setting (prior CDK4/6 inhibitors permitted in the adjuvant setting provided there was a CDK4/6i treatment free interval of at least 12 months).
- •12.More than 1 line of chemotherapy for metastatic disease.
研究者
相似试验
招募中
1 期
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-292)Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast CancerCTIS2023-504997-39-00AstraZeneca AB629
暂停
3 期
A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)ocally Advanced (Inoperable) or Metastatic Breast CancerJPRN-jRCT2031220034Hibi Kazushige82
尚未招募
3 期
How Calcarea carbonica 200c Homoeopathic Medicine works in Pain Management of Knee Joint in Osteoarthritis among Women aged 45-65 YearsCTRI/2023/02/049604Dr.Sailee Mysker
尚未招募
2 期
Role of Homoeopathic medicines in treatment of children with worms.CTRI/2024/03/063707Raxitkumar Ramavat
招募中
不适用
To test the disease free survival (DFS) prediction ability of the OncoDiscover diagnostic technology â?? a simple liquid biopsy blood test for cancer patients.CTRI/2018/04/012920Actorius Innovations and Research Pvt Ltd